Faslodex
![In the US, patients with advanced HR-positive breast cancer are given priority review for the combination of capivasertib and Faslodex](https://pharmtales.com/wp-content/uploads/2023/06/In-the-US-patients-with-advanced-HR-positive-breast-cancer-are-given-priority-review-for-the-combination-of-capivasertib-and-Faslodex.jpg)
In the US, patients with advanced HR-positive breast cancer are given priority review for the combination of capivasertib and Faslodex
SG Tylor
Source- Astrazeneca The US Food and Drug Administration (FDA) has accepted and granted Priority Review to AstraZeneca’s New Drug Application ...